India’s medical device sector is undergoing rapid transformation driven by regulatory reforms, increased global participation, and a strong push toward quality and patient safety. The regulatory framework, primarily governed by the Medical Devices Rules (MDR), 2017 under the Drugs and Cosmetics Act, 1940, has evolved into a structured, risk-based, and increasingly digitized system. This article provides a comprehensive overview of the regulatory architecture, compliance requirements, and recent updates shaping India’s medical device ecosystem.
India represents one of the fastest-growing medical device markets globally. To ensure safety, quality, and efficacy, medical devices are regulated under the Drugs and Cosmetics Act, 1940 and the Medical Devices Rules, 2017 (MDR 2017).
The Central Drugs Standard Control Organization (CDSCO) serves as the national regulatory authority, overseeing approvals, licensing, and compliance.
The MDR 2017 provides a comprehensive framework covering manufacture, import, sale, and distribution of medical devices.
India follows a dual regulatory model:
| Authority | Role |
|---|---|
| CDSCO (Central Licensing Authority) | Import licenses, high-risk devices (Class C & D), clinical investigations |
| State Licensing Authority (SLA) | Manufacturing and sale of low-to-moderate risk devices (Class A & B) |
For example, CDSCO regulates import and high-risk manufacturing, while states handle lower-risk categories.
| Class | Risk Level |
|---|---|
| Class A | Low risk |
| Class B | Low-moderate risk |
| Class C | Moderate-high risk |
| Class D | High risk |
This classification aligns with global frameworks such as IMDRF and forms the basis for regulatory controls.
As of October 2023, most regulated devices require licensing prior to import or sale.
Foreign manufacturers must appoint an Authorized Indian Agent for regulatory submissions.
While ISO 13485 is widely accepted, it is not always mandatory but strengthens compliance credibility.
IVDs are regulated similarly to drugs under the Act, with specific licensing and evaluation requirements. CDSCO directly regulates higher-risk IVDs (Class C & D).
India has transitioned toward regulating all medical devices, eliminating earlier distinctions between notified and non-notified devices.
CDSCO proposed updates to risk classification across several device categories, including cardiovascular and radiology devices, aligning more closely with international standards.
Regulatory reforms aim to create a predictable and digitized ecosystem.
These updates significantly improve regulatory clarity and consistency.
The regulatory ecosystem is expected to become more robust, transparent, and innovation-friendly.
India’s medical device regulatory framework has evolved into a structured, risk-based system under MDR 2017. Continuous updates, digitalization, and global alignment are transforming the regulatory landscape. While compliance requirements are becoming more stringent, they are also enhancing product quality, patient safety, and market credibility.
